Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.

Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive liposarcoma associated with poor prognosis. First-line treatment for advanced/metastatic DDLPS is systemic chemotherapy, but efficacy is poor and toxicities substantial. Most DDLPS tumors have amplification of the MDM2 gene, which encodes a negative regulator of the p53 suppressor protein. BI 907828 is a highly potent, oral MDM2-p53 antagonist that inhibits the interaction between p53 and MDM2, thereby restoring p53 activity. BI 907828 has shown promising activity in preclinical studies and in a phase Ia/Ib study in patients with solid tumors, particularly those with DDLPS. This manuscript describes the rationale and design of an ongoing multicenter, randomized, phase II/III trial (Brightline-1; NCT05218499) evaluating BI 907828 versus doxorubicin as first-line treatment for advanced DDLPS.

[1]  P. Schöffski.  Established and Experimental Systemic Treatment Options for Advanced Liposarcoma , 2022, Oncology Research and Treatment.

[2]  M. Gounder,et al.  1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma , 2021, Annals of Oncology.

[3]  K. Nabeshima,et al.  Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives , 2021, Journal of clinical medicine.

[4]  A. B. Hassan,et al.  Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Gronchi,et al.  Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine , 2020, CA: a cancer journal for clinicians.

[6]  S. Sleijfer,et al.  Impact of primary tumor location on outcome of liposarcoma patients, a retrospective cohort study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  N. Chattipakorn,et al.  Effects of doxorubicin on the heart: From molecular mechanisms to intervention strategies. , 2019, European journal of pharmacology.

[8]  R. Sciot,et al.  Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification , 2019, Clinical and Translational Oncology.

[9]  R. Sciot,et al.  Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center , 2019, Oncology Research and Treatment.

[10]  J. Blay,et al.  Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study , 2017, BMC Medicine.

[11]  J. Ngeow,et al.  Sarcomas Associated With Genetic Cancer Predisposition Syndromes: A Review. , 2016, The oncologist.

[12]  Narasimhan P. Agaram,et al.  Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. , 2015, European journal of cancer.

[13]  A. Shinagare,et al.  Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients. , 2015, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[14]  R. Schilsky,et al.  Optimizing Dosing of Oncology Drugs , 2014, Clinical pharmacology and therapeutics.

[15]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[16]  J. Blay,et al.  Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Blay,et al.  Incidence of Sarcoma Histotypes and Molecular Subtypes in a Prospective Epidemiological Study with Central Pathology Review and Molecular Testing , 2011, PloS one.

[18]  C. Jennison,et al.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.

[19]  C. Creighton,et al.  Diagnosis, Management, and Outcome of Patients with Dedifferentiated Liposarcoma Systemic Metastasis , 2011, Annals of Surgical Oncology.

[20]  David M. Thomas,et al.  Liposarcoma: Molecular Genetics and Therapeutics , 2010, Sarcoma.

[21]  Cristina Carvalho,et al.  Doxorubicin: the good, the bad and the ugly effect. , 2009, Current medicinal chemistry.

[22]  Frank Bretz,et al.  TUTORIAL IN BIOSTATISTICS Adaptive designs for confirmatory clinical trials , 2022 .

[23]  M. Kattan,et al.  Subtype Specific Prognostic Nomogram for Patients With Primary Liposarcoma of the Retroperitoneum, Extremity, or Trunk , 2006, Annals of surgery.

[24]  Robin L. Jones,et al.  Differential sensitivity of liposarcoma subtypes to chemotherapy. , 2005, European journal of cancer.

[25]  Louis Guillou,et al.  MDM2 and CDK4 Immunostainings Are Useful Adjuncts in Diagnosing Well-Differentiated and Dedifferentiated Liposarcoma Subtypes: A Comparative Analysis of 559 Soft Tissue Neoplasms With Genetic Data , 2005, The American journal of surgical pathology.

[26]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[27]  Samuel Singer,et al.  Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.

[28]  J. Goldblum,et al.  Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation. , 1997, The American journal of surgical pathology.